在Cimicifuga heracleifolia公司. 通过PI3K/AKT/NF-κB信号通路减轻性结肠炎
Xue-Yi Wu1, Qin-Wei Dong1, Yong-Bo Zhang1
1State Key Laboratory of Component-based Chinese Medicine, Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, PR China.
Journal of ethnopharmacology
|October 12, 2024
概括
Cimicifuga heracleifolia通过加强肠道屏障和减少炎症,有效治疗性结肠炎 (UC). 这项研究确定了关键化合物及其治疗作用中的PI3K/AKT/NF-κB通路.
科学领域:
- 草药是一种草药.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- Cimicifuga heracleifolia (C. heracleifolia) 在胃肠道问题,如腹等方面表现有前途.
- 性结肠炎 (UC) 是一种慢性炎症状况,与腹 (splenasthenic diarrhea) 有病理相似之处.
- 在UC上C. heracleifolia的治疗作用和机制仍然在很大程度上未被研究.
研究的目的:
- 研究C. heracleifolia在治疗性结肠炎 (UC) 的治疗潜力.
- 在UC的背景下阐明C. heracleifolia的潜在药理机制.
主要方法:
- 网络药理学被用来预测治疗点和途径.
- 转录学和功能测试在DSS诱导的UC模型中验证了发现.
- 使用表面等离子体共振 (SPR),分子对接和基于细胞的测试来识别生物活性化合物.
主要成果:
- 网络分析确定了52种C. heracleifolia成分中的32个关键目标,表明免疫调节和抗炎作用.
- 在体内研究表明,结肠损伤减少,抑制炎症性细胞因子 (IL-1β,IL-6,TNF-α) 和改善紧结蛋白表达.
- 鉴定出西米根oside,咖啡酸和甲基咖啡酸是负责UC治疗的关键生物活性化合物.
结论:
- C. heracleifolia通过增强肠粘膜屏障功能来改善UC.
- 治疗效果与PI3K/AKT/NF-κB信号通路的抑制有关.
- 这些发现支持C. heracleifolia在治疗性结肠炎的临床应用.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
126
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
126
01:21Drugs for Treatment of Constipation-Predominant IBS
140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118